4,6-双(4-氟苯基)-2-甲基-5-(4-吡啶基)-2H-吡唑并[3,4-b]吡啶 | 755753-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4,6-双(4-氟苯基)-2-甲基-5-(4-吡啶基)-2H-吡唑并[3,4-b]吡啶
• 英文名称: UR-13756
• 英文别名: 4,6-Bis(4-fluorophenyl)-2-methyl-5-(4-pyridinyl)-2H-pyrazolo[3,4-b]pyridine；4,6-bis(4-fluorophenyl)-2-methyl-5-pyridin-4-ylpyrazolo[3,4-b]pyridine
• CAS: 755753-89-0
• 化学式: C₂₄H₁₆F₂N₄
• 分子量: 398.415
• InChiKey: VMAKTIDYMSNPOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-甲基吡啶 、 对氟苯甲酸乙酯 在 盐酸 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 4.5h， 生成 4,6-双(4-氟苯基)-2-甲基-5-(4-吡啶基)-2H-吡唑并[3,4-b]吡啶
  参考文献：
  名称：

  Regiocontrolled synthesis of 3- and 5-aminopyrazoles, pyrazolo[3,4-d]pyrimidines, pyrazolo[3,4-b]pyridines and pyrazolo[3,4-b]quinolinones as MAPK inhibitors

  摘要：

  Microwave irradiation of a hydrazine and 3-methoxyacrylonitrile, ethoxymethylenemalononitrile or ethyl acetoacetate provides rapid access to 3- or 5-substituted pyrazoles in excellent yield and with total regiocontrol in a process that can be switched from one regioisomer to the other by choice of conditions. Subsequent reaction, either by microwave-assisted hydrolysis and cyclocondensation with formamide, Hantzsch-type three-component reaction with an aldehyde and ketone, or by cyclocondensation with 2-nitrobenzaldehyde, provides the pyrazolo[3,4-d]pyrimidine, pyrazolo[3,4-b]pyridine or pyrazolo[3,4-b]quinolin-4-one framework, respectively, of inhibitors of mitogen-activated protein kinases. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.07.055

文献信息

• [EN] PYRAZOLOPYRIDINE DERIVATES<br/>[FR] DERIVES DE PYRAZOLOPYRIDINE
  申请人：URIACH Y COMPANIA S A J

  公开号：WO2004076450A1

  公开（公告）日：2004-09-10

  New compounds of formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.

  公式（I）的新化合物及其盐、溶剂合物和前药，其中各种取代基的含义如描述中所披露的。这些化合物可用作p38激酶抑制剂。
• Pyrazolopyridine derivates
  申请人：Almansa Rosales Carmen

  公开号：US20060167040A1

  公开（公告）日：2006-07-27

  New compounds of formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.

  新化合物的公式为（I），以及其盐，溶剂合物和前药，其中各种取代基的含义如描述所示。这些化合物可用作p38激酶抑制剂。
• Pyrazolopyridine Derivates
  申请人：Almansa Rosales Carmen

  公开号：US20090005377A1

  公开（公告）日：2009-01-01

  New compounds of formula (I) and the salts thereof, wherein the meanings for the various substituents are as disclosed in the description, are useful as p38 kinase inhibitors.

  公式（I）及其盐的新化合物，其中各取代基的含义如说明中所披露，可用作p38激酶抑制剂。
• P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
  申请人：Fulcrum Therapeutics, Inc.

  公开号：US10342786B2

  公开（公告）日：2019-07-09

  The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.

  本发明公开了包括 p38 激酶抑制剂和调节 DUX4 及下游基因（包括但不限于 ZSCAN4、LEUTX、PRAMEF2、TRIM43、MBD3L2、KHDC1L、RFPL2、CCNA1、SLC34A2、TPRX1、PRAMEF20、TRIM49、PRAMEF4、PRAME6、PRAMEF15 或 ZNF280A）表达的制剂在内的方法和组合物。本研究公开了用于治疗与 DUX4 及下游基因表达异常有关的疾病（如筋膜囊性肌营养不良症）的方法。
• Methods and compounds for the treatment or prevention of severe influenza
  申请人：Orph Pharma IP Company Limited

  公开号：US11339207B2

  公开（公告）日：2022-05-24

  A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza maybe characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner.

  用于治疗或预防人类患者重症流感的 p38 MAPK 抑制剂。在某些实施方案中，重症流感的特征可能是一种或多种促炎细胞因子水平升高的高细胞因子血症。p38 MAP 激酶抑制剂可抑制内皮细胞释放此类促炎介质。在某些实施方案中，p38 MAP 激酶抑制剂可抑制内皮细胞释放 IP 10，最好是以剂量依赖的方式。